Precipio (PRPO) to Release Earnings on Wednesday

Precipio (NASDAQ:PRPO) is projected to issue its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of ($2.00) per share and revenue of $1.6750 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Precipio (NASDAQ:PRPO) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) EPS for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The business had revenue of $6.71 million during the quarter.

Precipio Price Performance

Precipio stock opened at $23.70 on Wednesday. The firm has a market capitalization of $42.42 million, a PE ratio of -50.43 and a beta of 1.27. Precipio has a 52 week low of $13.02 and a 52 week high of $33.63. The firm’s 50-day simple moving average is $23.99 and its 200 day simple moving average is $25.19. The company has a quick ratio of 1.33, a current ratio of 1.56 and a debt-to-equity ratio of 0.05.

Wall Street Analysts Forecast Growth

PRPO has been the subject of a number of research reports. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research report on Friday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Precipio

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in shares of Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares during the period. Renaissance Technologies LLC boosted its position in Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Precipio in the 3rd quarter worth approximately $194,000. 10.45% of the stock is currently owned by hedge funds and other institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.